Hemophilia A
Takeda Inks $3.6 Billion Deal with Poseida to Advance Non-Viral Gene Therapies and Overcome Safety Issues
2021-10-13
FDA Rejects BioMarin Pharmaceuticals’ Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
2020-08-20
Sangamo’s Shares Goes up after the Announcement of Investigational Hemophilia A Gene Therapy Results
2019-07-19